Table 3.
Comparison of baseline characteristics between patients and retrospective controls
| Patients n = 10 | Retrospective controls n = 38 | P value | ||
| Age | 68.5 (28–83) | 73 (40–89) | Ns† | |
| Sex, n (%) | ||||
| Male | 6 (60%) | 30 (79%) | Ns‡ | |
| Female | 4 (40%) | 8 (21%) | ||
| Smoking status n (%) | ||||
| Never | 2 (20%) | 7 (18%) | Ns‡ | |
| Former or current | 8 (80%) | 31 (82%) | ||
| Histological type n (%) | ||||
| Adenocarcinoma | 7 (70%) | 29 (76%) | Ns‡ | |
| Squamous cell carcinoma | 2 (20%) | 9 (24%) | ||
| Adenosquamous carcinoma | 1 (10%) | 0 | ||
| Best response of chemotherapy n (%) | ||||
| PR or SD | 8 (80%) | 35 (92% | Ns‡ | |
| PD | 2 (20%) | 3 (8%) | ||
| CINV | ||||
| Nausea* | ||||
| All grade | 8 (80%) | 22 (58%) | Ns‡ | |
| Grade 3/4 | 1 (10%) | 2 (5%) | ||
| Vomiting* | ||||
| All grade | 2 (20%) | 4 (11%) | Ns‡ | |
| Grade 3/4 | 1 (10%) | 2 (5%) | ||
| TP (g dL-1) | 7.18 ± 0.63 | 7.15 ± 0.59 | Ns† | |
| Alb (g dL-1) | 3.88 ± 0.41 | 4.00 ± 0.44 | Ns† | |
| WBC (uL-1) | 9400 ± 4500 | 8000 ± 3500 | Ns† | |
| Hb (g dL-1) | 13.2 ± 1.34 | 13.0 ± 1.57 | Ns† | |
| Plt (×103 uL-1) | 304 ± 110 | 260 ± 63 | Ns† | |
| Cr (mg dL-1) | 0.63 ± 0.10 | 0.73 ± 0.19 | Ns† | |
| LDH (U L-1) | 257 ± 137 | 226 ± 71.4 | Ns† | |
| CRP (mg dL-1) | 1.73 ± 1.76 | 1.15 ± 1.44 | Ns† | |
*Adverse event was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Event (version 4.0).
†Mann-Whitney test; ‡chi-square test.
Alb, albumin; CINV, chemotherapy-induced nausea and vomiting; Cr, creatinine; CRP, c-reactive protein; Hb, hemoglobin; LDH, lactic acid dehydrogenase; n, number of cases (% total cases); Ns, not significant; PD, progressive disease; Plt, platelet; PR, partial response; SD, stable disease; TP, total protein; WBC, white blood cell.